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Behavioral/Systems/Cognitive
Long-Term Consequences of Methamphetamine Exposure in
Young Adults Are Exacerbated in Glial Cell Line-Derived
Neurotrophic Factor Heterozygous Mice
Heather A. Boger,1 Lawrence D. Middaugh,1,2 Kennerly S. Patrick,3 Sammanda Ramamoorthy,1 Emily D. Denehy,1
Haojie Zhu,3 Alejandra M. Pacchioni,1 Ann-Charlotte Granholm,1 and Jacqueline F. McGinty1,2
1Department of Neurosciences and Center on Aging, and 2Departments of Psychiatry and Behavioral Sciences, and 3Pharmaceutical Sciences, Medical
University of South Carolina, South Carolina 29425
Methamphetamine abuse in young adults has long-term deleterious effects on brain function that are associated with damage to mono-
aminergic neurons. Administration of glial cell line-derived neurotrophic factor (GDNF) protects dopamine neurons from the toxic
effects of methamphetamine in animal models. Therefore, we hypothesized that a partial GDNF gene deletion would increase the suscep-
tibility of mice to methamphetamine neurotoxicity during young adulthood and possibly increase age-related deterioration of behavior
and dopamine function. Two weeks after a methamphetamine binge (4  10 mg/kg, i.p., at 2 h intervals), GDNF / mice had a signifi-
cantly greater reduction of tyrosine hydroxylase immunoreactivity in the medial striatum, a proportionally greater depletion of dopa-
mine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the striatum, and a greater increase in activated microglia in the substantia
nigra than wild-type mice. At 12 months of age, methamphetamine-treated GDNF / mice exhibited less motor activity and lower levels
of tyrosine hydroxylase-immunoreactivity, dopamine, DOPAC, and serotonin than wild-type mice. Greater striatal dopamine transporter
activity in GDNF / mice may underlie their differential response to methamphetamine. These data suggest the possibility that meth-
amphetamine use in young adults, when combined with lower levels of GDNF throughout life, may precipitate the appearance of
parkinsonian-like behaviors during aging.
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Introduction
Use of methamphetamine (METH), a powerfully addictive psy-
chostimulant, is highest among young adults ages 18 –25 in the
United States (Substance Abuse and Mental Health Services Ad-
ministration Office of Applied Statistics National Survey on Drug
Use and Health Report, 2006, Figure 5.4, p 50). METH binds to
monoamine transporters and is transported into monoaminergic
terminals, causing increased cytosolic release and, ultimately, de-
pletion of dopamine (DA) and serotonin (5-HT) as well as their
synthetic enzymes, tyrosine hydroxylase (TH) and tryptophan
hydroxylase, respectively (Hotchkiss and Gibb, 1980; Wagner et
al., 1980; Bakhit et al., 1981; Kita et al., 2003). High doses of
METH damage monoaminergic terminals and transporters in
the striatum of humans (Volkow et al., 2001) and experimental
animals (Ricuarte et al., 1982; Sonsalla et al., 1992). METH-
induced hyperthermia (Bowyer et al., 1992; O’Callaghan and
Miller, 1994), glutamate excitotoxicity (Sonsalla et al., 1986,
1992; Mark et al., 2004), increased production of reactive oxygen
species (Yamamoto and Zhu, 1998; LaVoie et al., 1999), and mi-
croglia activation (LaVoie et al., 2004) all contribute to the acute
toxic effects of METH. Despite some functional recovery over
time, suppressed striatal metabolism and psychomotor impair-
ment are prolonged in abstinent human METH abusers (Wang
and Volkow, 2004). Furthermore, because the function of the
nigrostriatal dopamine system decreases with age, it has been
suggested that people who abuse METH early in life may be more
at risk for developing parkinsonian-like motor deficits as they age
(Volkow et al., 2001).
Glial cell line-derived neurotrophic factor (GDNF) is required
for the survival, high-affinity DA uptake, and neurite outgrowth
of midbrain DA and 5-HT neurons (Lin et al., 1993; Krieglstein et
al., 1995; Galter and Unsicker, 1999; Ducray et al., 2006). Impor-
tantly, GDNF is decreased in the substantia nigra (SN) of Parkin-
son’s disease patients (Jenner and Olanow, 1998) and also in
normal aged rodents (Yurek and Fletcher-Turner, 2001), sug-
Received Aug. 11, 2006; revised June 11, 2007; accepted June 27, 2007.
This work was supported by National Institutes of Health Grants R01 DA03982 (J.F.M.), PO1 AG023630 (A.-C.G.),
RO1 MH62612 (S.R.), and C06 RR015455 from the Extramural Research Facilities Program of the National Center for
Research Resources, and Department of the Army Medical Command Grant 17-99-1-9480 (A.-C.G.). H.A.B. per-
formed the behavioral experiments, immunohistochemical staining, and data analysis; L.D.M. supervised the be-
havioral data analysis; S.R. and Devadoss Samuel performed the DAT assays; K.S.P. and H.Z. measured brain meth-
amphetamine concentrations; and A.M.P. and H.A.B. performed the HPLC measurements; A.-C.G. and J.F.M.
supervised the project and provided the reagents; J.F.M. designed the project; A.-C. G. supported H.A.B., performed
statistical analyses, and provided the mice breeding support. H.A.B. wrote the paper with editorial input from
A.-C.G., L.D.M., and J.F.M. We thank Alfred Moore, Channon Reid, Devadoss Samuvel, and Vandana Zaman for
technical assistance. We thank Dr. Peter Kalivas for HPLC reagents, equipment, and manuscript review, Dr. Greg
Gerhardt for reviewing the HPLC data, and Dr. Barry Hoffer for providing the mouse strain and valuable advice.
Correspondence should be addressed to Jacqueline F. McGinty, Department of Neurosciences, Medical University
of South Carolina, 173 Ashley Avenue, Basic Science Building Suite 403, Charleston, SC 29425. E-mail:
mcginty@musc.edu.
DOI:10.1523/JNEUROSCI.1067-07.2007
Copyright © 2007 Society for Neuroscience 0270-6474/07/278816-10$15.00/0
8816 • The Journal of Neuroscience, August 15, 2007 • 27(33):8816 – 8825
gesting its involvement in motor dysfunction and DA neuronal
degeneration. Nigral GDNF reduction in Parkinson’s disease pa-
tients is not just caused by the loss of DA neurons per se, but also
by a reduction of GDNF expression in the remaining DA neu-
rons, suggesting that a lifelong deficit in GDNF may contribute to
DA cell loss and motor dysfunction during aging. Conversely,
GDNF promotes recovery of behavioral and morphological def-
icits in experimental models of Parkinson’s disease (Bowenkamp
et al., 1995; Mandel et al., 1997; Jenner and Olanow, 1998; Cass
and Manning, 1999; Kordower et al., 2000; Melega et al., 2000;
Yurek and Fletcher-Turner, 2001) and after METH toxicity
(Cass, 1996).
In GDNF knock-out mice, prenatal development of mesence-
phalic DA neurons is GDNF independent (Moore et al., 1996;
Pichel et al., 1996), whereas postnatal maturation of DA neurons
is GDNF dependent (Granholm et al., 2000). Furthermore, at 12
months of age, GDNF/ mice have fewer TH-positive neurons
in the SN and exhibit less motor activity than wild-type (WT)
mice (Boger et al., 2006). Therefore, we hypothesized that
METH-induced DAergic toxicity during adolescence would be
exacerbated in GDNF/ mice and that this “dual hit” would
have long-term behavioral and structural consequences in aging
mice.
Materials and Methods
Animals. GDNF / mice were compared with WT littermates in all
experiments. The nonfunctional allele for the GDNF gene was originally
generated by replacing part of the third exon that encodes the GDNF
protein with a cassette expressing the selectable marker neomycin phos-
photransferase, as described previously in detail (Pichel et al., 1996).
After introducing this construct into embryonic stem cells, six clones
were identified with the predicted mutant allele. CD1 or C57BL/6 recip-
ient strains were used to obtain germline transmission of the targeted
allele. Heterozygous offspring are viable and fertile, whereas mice ho-
mozygous for the mutant GDNF allele (GDNF /) die within 24 h of
birth. The mice for this study were bred locally at the Medical University
of South Carolina on a C57BL/6J background, weaned, and genotyped as
described previously (Boger et al., 2006), according to National Institutes
of Health (NIH)-approved protocols. The mice were housed in groups of
three or four to a cage and had ad libitum access to food and water. They
were maintained on a 12 h light/dark cycle at an ambient temperature of
20 –22°C.
Experimental design. When the GDNF / and WT mice reached 2.5
months of age, they were injected with METH (10 mg/kg, i.p., four times
at 2 h intervals) or saline (0.2 ml). Rectal temperatures were recorded 5
min before the first injection and 20 min after each of the four injections.
Motor activity was recorded in photocell chambers for 20 min after the
first and fourth injection, and 2 weeks postinjection when the mice were
3 months old. In one experiment, the selective DA uptake inhibitor,
nomifensine (7.5 mg/kg, i.p.), was injected immediately before locomo-
tor testing 2 weeks after METH or saline injections. In experiments in
which the mice lived until they were 12 months old, their spontaneous
locomotor activity was recorded for 20 min in the photocell chambers at
6, 9, and 12 months of age.
Body temperature measurements. Rectal temperature was measured
before the first injection and then 20 min after each intraperitoneal in-
jection with a TH-5 Thermalert Monitor Thermometer (Physitemp In-
struments, Clinton, NJ) by holding each mouse at the base of the tail and
inserting a probe (RET-3) 2.0 cm past the rectum and into the colon until
a rectal temperature was maintained for 3 s.
Locomotor testing. GDNF / and WT mice were tested after the first
and fourth injections of either saline or METH, 2 weeks postinjection
and, in the longevity studies at 6, 9, and 12 months of age. Locomotor
activity (total distance traveled) was assessed in a Digiscan Animal Activ-
ity Monitor system [model RXYZCM(8) TAO; Omnitech Electronics,
Columbus, OH]. The details of the apparatus have been described pre-
viously (Halberda et al., 1997). On the day of testing, the mice were
transferred from the animal colony into the laboratory in groups of six
and tested in a darkened environment. Data were collected in 1 min
intervals for 20 min at the same time of day (8 A.M. to 12 P.M.) for each
test period.
Immunohistochemistry. At 3 (2 weeks postinjection) and 12 months of
age, mice were anesthetized with halothane and perfused transcardially
with saline followed by 4% paraformaldehyde in phosphate buffer (0.1 M,
pH 7.4). The brains were removed, postfixed in 4% paraformaldehyde
for 24 h, and then transferred to 30% sucrose in 0.1 M PBS for at least 24 h
before sectioning for histochemical analysis. The striatum and midbrain
were sectioned on a cryostat (Microm; Zeiss, Thornwood, NY) at 45 m.
Sections through the striatum and SN were processed for free-floating
immunohistochemistry using a rabbit polyclonal antibody against TH
(1:5000; Pel-Freeze Biologicals, Roger, AZ, USA) or a rat anti-mouse
antibody against the cluster differentiation (CD) marker, CD45
(MCA1388; 1:1000; Serotec, Raleigh, NC). Immunodetection was per-
formed using the avidin-biotin-immunoperoxidase method (Choe and
McGinty, 2000). Briefly, after a 5 min pretreatment with 2% Triton-X to
allow penetration into the tissue, a subset of sections from each mouse
was incubated simultaneously in the primary antisera against TH or
CD45 for 24 h at 4°C. The sections were then rinsed and incubated for 1 h
in biotin-conjugated goat anti-rabbit (TH) or goat anti-rat (CD45) IgG,
rinsed, and incubated for 1 h in avidin-biotin-peroxidase reagents (Elite
Vectastain kit; Vector Laboratories, Burlingame, CA). The reaction was
developed by staining with VIP (Vector Laboratories), which yields a
purple reaction product. Each of the above steps was separated by three
10 min washes in PBS. Sections were mounted on glass slides and cover-
slipped with distrene plasticizer xylene.
Semiquantitation of immunostaining. Analysis of medial and lateral
striatal subregions and the nucleus accumbens was performed using the
NIH Image program as described previously (Choe and McGinty, 2000).
Briefly, background was subtracted and the Look Up Table scale was
adjusted using density slicing. This approach captures all labeled profiles
above a threshold density and interactively discriminates them from den-
sity values below the threshold. The software then automatically mea-
sures the mean optical density and number of pixels per area of the
extracted profiles in the selected medial or lateral striatal regions. Two
parameters were obtained from this procedure: the area covered by the
specific profile population (field area) and the mean density of the spe-
cific profiles. The integrated density was obtained by multiplying the field
area times the mean density value.
Stereological cell counts. Quantitative estimates of the total number of
TH-immunoreactive neurons in the SN were achieved using an unbi-
ased, stereological cell-counting method as described previously (Gran-
holm et al., 2002). Briefly, the optical fractionator system consists of a
computer-assisted image-analysis system including a Nikon (Tokyo, Ja-
pan) Eclipse E-600 microscope hard-coupled to a Prior H128 computer-
controlled x-y-z motorized stage, an Olympus (Tokyo, Japan) 750 video
camera system, a Micron Pentium III 450 computer (Nampa, ID), and
stereological software (Stereoinvestigator; MicroBrightField, Colchester,
VT). The SN was outlined under low magnification (10) on every third
section through the rostrocaudal extent of the midbrain and the outlined
region was measured with a systematic random design of dissector
counting frames (100  100 m). Actual mounted section thickness was
found to be 35–37 m, and a 2 m guard zone was set for the top and
bottom of each section. A 40 objective lens with a 1.4 numerical aper-
ture was used to count cells within the counting frames.
Measurement of 5-HT and DA in brain tissue. At 3 (2 weeks postinjec-
tion) and 12 months of age, mice were killed and the striata were dis-
sected unilaterally and frozen at 80°C. The tissue samples were placed
in 300 l of mobile phase containing 0.2 M isoproterenol as an internal
standard, sonicated, and centrifuged (2 min at 13,000 rpm). The concen-
tration of DA and 5-HT in the supernatant was measured by injecting 5
l of the supernatant into the high-performance liquid chromatography
(HPLC). An ESA (Chelmsford, MA) pump (model 582) was used to
deliver 0.5 ml/min of mobile phase (0.1 M trichloroacetic acid, 0.01 M
sodium acetate, 0.1 mM EDTA, and 16% MetOH, pH  4.1) to a reversed
phase column (ESA HR-80). After separation from the column, the bio-
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genic amines were oxidized/reduced using coulometric detection (Cou-
lochem II; ESA). Three electrodes were used: a guard cell (0.40 V), a
reduction analytical electrode (E1, 0.15 V), and an oxidation analytical
electrode (E2, 0.325 V). The peak areas were measured with an ESA 501
Chromatography Data System and the values were compared with an
external standard curve for quantification. The final data were evaluated
as nanograms per gram of wet tissue weight.
Striatal and plasma METH concentrations. Striatal tissue (9 –31 mg)
and blood plasma were analyzed for METH concentrations 30, 60, 120,
and 180 min after the last of four 10 mg/kg intraperitoneal METH injec-
tions in 2.5-month-old WT and GDNF / mice (n  5 for each time
point) using gas chromatography–mass spectrometry. Briefly, when the
appropriate time from the last injection was reached (30, 60, 120, 180
min), mice were anesthetized with Equithesin (1 mg/kg, i.p.) and a retro-
orbital sinus blood sample was immediately obtained. Blood was initially
collected in 44.7 l of heparinized microcapillary pipettes before being
transferred to a 0.5 ml Eppendorf (Hamburg, Germany) tube for storage
on ice at 4°C. Each mouse then underwent a rapid decapitation and the
whole striatum was removed and stored on dry ice. Once dissections were
complete, blood samples were spun at room temperature at 10,000 rpm
for 10 min in an Eppendorf model 5415C centrifuge. The plasma was
aspirated from the red blood cell pellet and assayed.
A novel method using NiCl-selected ion monitoring of ions 275 amu
(METH minus hydrogen fluoride) and 283 amu [nonadeutero (D9)-
METH minus deuterium fluoride] was developed to measure METH
concentrations in plasma and brain. Samples were extracted by a process
modified from a process described previously (Johnson-Davis et al.,
2004). Frozen striatal tissue was thawed and suspended in distilled water,
fortified with 100 ng of D9-METH (Cerilliant, Round Rock, TX) as an
internal standard, homogenized (Polytron), sonicated, alkalinized with
concentrated NH4OH (0.1 ml), and then extracted with butyl chloride/
acetonitrile (4:1). After centrifugation, the organic phase was transferred
to a silanized vial and pentafluoropropionic anhydride (PFPA; 40 l) was
added by vortexing to generate acid in situ for trapping METH as the
nonvolatile salt. After 10 min, nitrogen was used to evaporate the sample
to dryness and again PFPA (50) was added, followed by capping and
derivatization at 42°C for 30 min. The sample was cooled to 25°C, evap-
orated to dryness under nitrogen, and then the residue was dissolved in
heptane (50 l) and transferred to a silanized microvial insert for gas
chromatographic (GC) autoinjection. Calibrator samples used blank
mouse brain tissue (25 mg) spiked with METH (Cerilliant) and were
processed in parallel with the unknowns, yielding a highly linear standard
plot (r  0.9996). The GC–mass spectrometric (MS) method yielded ion
chromatograms devoid of chemical interferences.
Synaptosome preparation. Mice were decapitated and the striatum was
immediately homogenized in 10 volumes (w/v) of cold 0.32 M sucrose.
The crude synaptosomal pellet (P2 fraction) was further purified as de-
scribed previously (Samuvel et al., 2005). The purified synaptosomes
were suspended in regular Krebs–Ringer HEPES buffer saturated with
95% O2/5% CO2. Protein concentration was determined by a DC protein
assay (Bio-Rad, Hercules, CA) using bovine serum albumin as the
standard.
DA uptake. Purified synaptosomes (10 –20 g) were incubated in 250
l of assay buffer containing 0.1 mM ascorbic acid, 0.1 mM pargyline, and
20 nM [ 3H]DA for 3 min as described previously (Samuvel et al., 2005).
Nonspecific [ 3H]DA uptake was defined as the accumulation in the pres-
ence of 100 M cocaine and was subtracted from total uptake. Uptake was
terminated by addition of 3 ml of ice-cold stop buffer (PBS containing
100 M nomifensine) followed by rapid filtration over 0.3%
polyethyleneimine-coated Glass Fiber/B filters using a Brandel (Gaith-
ersburg, MD) Cell Harvester. Filters were washed rapidly with 5 ml of
cold stop buffer and radioactivity bound to the filter was counted by
liquid scintillation spectrometry. All uptake assays were performed in
triplicate and mean values of specific uptake  SEM from at least three
separate experiments were determined.
DAT immunoblotting. Dopamine transporter (DAT) immunoblotting
was performed on detergent extracts of synaptosomes using an affinity
purified DAT-specific antibody raised as described previously (Samuvel
et al., 2005). Protein samples (25 g) were separated using 4 –15% linear
gradient SDS-PAGE, transferred to a polyvinylidene difluoride mem-
brane and probed with the DAT antibody as indicated in the figure
legends. Immunoreactive bands were visualized by ECL plus reagent.
Subsequently, the blots were striped and reprobed with calnexin antibod-
ies to validate transfer and the total amount of protein used. DAT band
densities were normalized using levels of calnexin to preclude errors
accompanying with sample loading/transfer and values were averaged
across three experiments. Band densities were quantified by scanning
and analyzed using NIH Image software.
Statistical analysis. Body temperature, locomotor activity, HPLC, ste-
reological cell counts, immunohistochemical densitometry, DAT activ-
ity, and immunoreactivity data were analyzed by mixed-factor ANOVAs
followed by Student–Neuman–Keuls tests for individual group compar-
isons. METH concentration data for GDNF / versus WT mice were
analyzed with a two-tailed Student’s t test.
Results
METH effects on behavior are exacerbated in GDNF / mice
METH, administered in a frequently used binge paradigm (10
mg/kg, i.p., four times at 2 h intervals) (Sonsalla et al., 1992;
Yamamoto and Zhu, 1998) increased body temperatures and al-
tered motor activity in 2.5-month-old GDNF/ and WT mice
(Fig. 1) without causing any mortality. A mixed-factor ANOVA
revealed a significant effect of treatment, but not genotype on
body temperatures after the second (F(1,16)  49.5; p  0.001),
third (F(1,16)  46.6; p  0.001), and fourth (F(1,16)  93.0; p 
0.001) injections (Fig. 1A). Similarly, METH treatment, regard-
less of genotype, significantly increased motor activity after the
first injection (F(1,16)  10.6; p  0.001) (Fig. 1B) and reduced
motor activity after the fourth injection (F(1,16)  30.2; p  0.001)
(Fig. 1C) to the same extent in both genotypes. Two weeks after
METH or saline, a separate cohort of GDNF/ and WT mice
was challenged with saline or the DAT uptake inhibitor, nomi-
fensine (Fig. 1D). The locomotor activity of all mice challenged
with saline did not differ from each other whereas those chal-
lenged with nomifensine demonstrated a significant increase in
locomotor activity (F(1,24)  284.7; p  0.001). However, there
was a significant METH by nomifensine interaction (F(1,24) 
21.99; p  0.001) whereby nomifensine elevated activity of
saline-pretreated mice to a greater extent than that of mice that
had undergone the METH binge (Fig. 1D). Thus, the DAT up-
take inhibition challenge revealed a METH-induced motor activ-
ity deficit not apparent without the drug challenge.
Another cohort of mice, treated similarly at 2.5 months of age
with METH or saline, lived until 12 months of age and their
locomotor activity was tested every 3 months without additional
drug challenge. At 9 months of age, but not 6 months of age (data
not shown), mice of both genotypes that had undergone the
METH binge as young adults were less active than saline-treated
mice (F(1,26)  33.5; p  0.001) (Fig. 1E). In contrast, a two-
factor between-groups ANOVA on locomotor activity data at 12
months of age revealed a significant interaction of METH by
genotype (F(1,26)  18.0; p  0.001). Comparison of means across
the four groups with a one-way ANOVA followed by Student–
Neuman–Keuls tests indicated that saline-injected GDNF/
mice were significantly less active than age-matched WT saline
controls ( p  0.01) at 12 months of age, confirming our previous
results (Boger et al., 2006). Moreover, 12-month-old GDNF/
mice were significantly less active than age-matched WT mice
exposed to METH as young adults ( p  0.01) (Fig. 1F). These
data suggest that partial GDNF depletion coupled with METH
exposure produced an additive behavioral deficit during aging
that emerged many months after the original insult.
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METH effects on TH in the striatum are exacerbated in
GDNF / mice
On preliminary visual inspection, there were apparent differ-
ences in the intensity of TH-immunoreactivity (IR) in the medial
and lateral regions of the dorsal striatum 2 weeks after METH or
saline injections (Fig. 2). Therefore, medial and lateral striatal
areas were analyzed independently by densitometry. ANOVA re-
vealed an overall treatment effect (F(1,16)  1525.4; p  0.001),
but no genotypic effect or interaction, for TH-IR values in the
lateral striatum (Fig. 2E, right). METH reduced TH-IR in the
lateral striatum 97% (WT) and 99% (GDNF/) compared with
saline controls (Fig. 2C–E, right). In contrast, in the medial stri-
atum, there were significant treatment (F(1,16)  24.1; p  0.001)
and genotype (F(1,16)  16.8; p  0.001) effects, but no interac-
tion (F(1,16)  0.146; p  0.05) of the two factors. A one-way
ANOVA followed by pairwise comparisons revealed that TH-IR
in the medial striatum of saline-injected GDNF/ mice was
significantly lower (32%) than that of saline-treated WT mice
( p  0.05) (Fig. 2A,B,E, left) and METH produced a signifi-
cantly greater decrease in TH-IR in GDNF/ (89%) than in WT
(55%) mice (Fig. 2C–E, left). There was no significant effect of
METH on TH-IR in the nucleus accumbens shell or core (sup-
plemental Table 1, available at www.jneurosci.org as supplemen-
tal material). Striatal TH-IR in 12-month-old GDNF/ and WT
mice after administration of a toxic regimen of METH at 2.5
months of age is quantified in Figure 2F. At this age, in the lateral
striatum, ANOVA revealed overall genotypic (F(1,20)  28.3; p 
0.001) and treatment (F(1,20)  12.5; p  0.01) effects, but no
interaction, indicating a deficit in recovery from the METH-
induced insult in the lateral striatum in both genotypes. Compar-
ison across groups with a one-way ANOVA (F(3,20)  15.0; p 
0.001) and Student–Neuman–Keuls pairwise comparisons indi-
cated that TH-IR in the lateral striatum was significantly less in
saline-treated GDNF/ mice than in WT mice ( p  0.05) (Fig.
2F, right) and that TH-IR was significantly less in both genotypes
treated with METH when they were young ( p  0.05). Moreover,
TH-IR in GDNF/ mice was less than in WT mice treated with
METH ( p  0.05). In the medial striatum, ANOVA revealed a
genotypic effect (F(1,20)  13.7; p  0.001), but no treatment
effect or interaction. Additional analysis using a one-way
ANOVA (F(3,20)  5.8; p  0.05) and Student–Neuman–Keuls
pairwise comparisons indicated that TH-IR in the medial stria-
tum was significantly less in GDNF/ versus WT mice treated
with saline, but not METH (Fig. 2F, left). At 12 months of age, no
significant difference existed between groups with TH-IR in the
nucleus accumbens shell or core (supplemental Table 1, available
at www.jneurosci.org as supplemental material).
Stereological cell counts revealed no difference in the number
of SN TH-positive neurons among the four groups at 2 weeks
postinjection (data not shown), suggesting that the effects of the
METH-binge paradigm were restricted to striatal terminals in
both genotypes at this age. In contrast to these results in young
adults, a two-way ANOVA on data collected from 12-month-old
mice revealed an overall genotypic effect (F(1,24)  7.3; p  0.01),
but no treatment effect or interaction. Additional analysis using a
one-way ANOVA (F(3,24)  3.938; p  0.05) and Student–Neu-
man–Keuls pairwise comparisons indicated that the number of
TH-positive neurons in the SNs of 12-month-old, saline-treated
GDNF/ mice (2884  26 neurons) was significantly fewer
( p  0.05) than the number in saline-treated WT mice (3872 
25 neurons). However, the number of TH-positive neurons did
not differ between saline-treated and METH-treated mice at this
age. Thus, METH treatment did not affect the number of SN DA
cell bodies in either of the genotypes tested, either 2 weeks or 10
months after the METH binge.
METH exacerbates SN microglial activation in 3-month-old
GDNF / mice
Reactive microglia are characterized by increased cell body vol-
ume; short, thick processes, and increased intensity of staining
for cell surface markers, such as CD antigens (LaVoie et al., 2004).
Activated microglia detected with CD45 immunostaining in the
Figure 1. METH-induced hyperthermia and locomotor activity did not differ between
GDNF / and WT mice initially, but differences in locomotor activity were revealed as the mice
aged. A, A significant increase in body temperature occurred in METH versus saline-treated mice
that did not differ between genotypes (*p  0.05 vs WT Saline and GDNF / Saline). n  5
per group. B, After the first injection, regardless of genotype, mice treated with METH were
significantly more active than saline-treated mice (***p 0.001). n 5 per group. C, After the
fourth injection, mice treated with METH, regardless of genotype, were hypoactive when com-
pared with saline-treated mice (***p  0.001). n  5 per group. D, Two weeks after the
injections (3 months of age), there were no differences in spontaneous motor activity among
the groups challenged with saline. In contrast, METH binge-pretreated mice challenged with
nomifensine 2 weeks later exhibited significantly less activity than those pretreated with saline
(***p  0.001). E, At 9 months of age, mice treated with METH, regardless of genotype,
exhibited less locomotor activity than saline-treated mice (***p  0.001). n  8 per group. F,
At 12 months of age, saline-pretreated GDNF / mice displayed less motor activity than WT
mice (**p 0.01). METH-treated GDNF / mice exhibited less motor activity than GDNF /
mice treated with saline or METH-treated WT mice (*p  0.05; **p  0.01; ***p  0.001).
n  8 per group. Error bars indicate SEM.
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striatum and SN are illustrated in Figure 3. A two-way ANOVA
revealed significant genotypic (F(1,16)  28.4; p  0.05) and treat-
ment (F(1,16)  10.4; p  0.05) effects with no interaction. Addi-
tional analysis using pairwise comparisons of means after a one-
way ANOVA (F(3,16)  13.2; p  0.01) indicated that the SNs of
GDNF/ mice treated with saline had significantly more CD45
immunostaining than WT mice ( p  0.05), suggesting increased
microglial activation (Fig. 3A,B,I). In WT mice, METH treat-
ment did not cause a significant increase in CD45-IR (Fig.
3A,C,I) whereas in GDNF/ mice, METH treatment caused a
significantly greater increase in CD45-IR in the SN than in either
saline-treated GDNF/ mice or METH-treated WT mice ( p 
0.05) (Fig. 3C,D, I). In contrast, no differences were detected in
CD45-IR in the striatum 2 weeks after injection (Fig. 3E–H,J). In
12-month-old mice, no alterations in CD45-IR were detected in
the striatum or SN of any of the four treatment groups (data not
shown). These data indicate that GDNF/ mice have activated
microglia in the SN in the absence of a challenge and that METH
exacerbates this activity transiently.
METH effects on DA and 5-HT levels are exacerbated in
GDNF / mice
A two-by-two ANOVA on data from 3-month-old mice revealed
an overall genotype-by-treatment interaction for striatal DA lev-
els (F(1,16)  15.1; p  0.01) and for striatal 3,4-dihydroxy-
phenylacetic acid (DOPAC) levels (F(1,16)  9.1; p  0.01). How-
ever, only METH treatment, but not genotype differences were
revealed for the DA/DOPAC ratio (F(1,16)  40.3; p  0.001) and
striatal 5-HT levels (F(1,16)  50.1; p  0.001) (Fig. 4C,D). Pair-
wise comparisons indicated that striatal DA and DOPAC levels
Figure 2. After METH treatment, 3- and 12-month-old GDNF / mice demonstrated a greater
loss of striatal TH-IR than WT mice. A–D, Photomicrographs of TH-IR in coronal hemisections of the
striatum (medial to the left; lateral to the right) from 3-month-old saline-treated WT mice (A), saline-
treated GDNF / mice (B), METH-treated WT mice (C), and METH-treated GDNF / mice (D). E,
Quantitation of the average integrated density from the four treatment groups at 3 months of age
confirmed that there were no differences in the lateral region (right) of the striatum between the
GDNF /and WT mice treated with saline, and METH induced a similar TH-IR depletion in the lateral
striatum of GDNF /and WT mice when compared with saline-treated mice (***p0.001). In the
medial striatum (left), GDNF / mice expressed less TH-IR than WT mice treated with saline (*p 
0.05), and METH induced a greater depletion in the medial striatum of GDNF / than WT mice
(*p  0.05). F, Quantitation of the average integrated density of TH-immunoreactive sections from
the four treatment groups at 12 months of age demonstrated that TH-IR levels were significantly less
in both the lateral and medial striatum of GDNF / mice versus WT mice treated with saline (*p 
0.05), that there was a residual deficit in TH-IR in METH- versus saline-treated WT mice in the lateral
region of the striatum (right; *p  0.05), and that there was significantly less TH-IR in the lateral
striatum of GDNF / versus WT mice treated with METH (*p 0.05). Circles denote measurement
areas of the lateral (L) and medial (M) regions of the striatum. n  8 per group. Error bars indicate
SEM.
Figure 3. A–H, GDNF / mice treated with METH exhibited an inflammatory response in
the SN 2 weeks after injection. CD45-IR in the SN (A–D) and striatum (E–H ) in saline (SAL)-
treated WT mice (A, E), saline-treated GDNF / mice (B, F ), METH-treated WT mice (C, G), and
METH-treated GDNF / mice (D, H ). Scale bar, 0.5 mm. I, J, Quantitation of the average
integrated density of CD45-ir in the SN (I ) and striatum (J ). Saline-treated GDNF / mice had
more CD45-IR in the SN than saline-treated WT mice (*p  0.05). METH treatment caused a
significantly greater increase in CD45-IR in the SN of GDNF / mice than in saline-treated
GDNF / mice or METH-treated WT mice (*p  0.05). n  5 per group. Error bars indicate
SEM.
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were significantly higher ( p  0.05) in GDNF/ mice than in
WT mice treated with saline (Fig. 4A,B). Striatal DA and DOPAC
levels were depleted to a similar extent in METH-treated
GDNF/ and WT mice 2 weeks after the injections ( p  0.05)
(Fig. 4A,B), resulting in a proportionally greater decrease for
GDNF/ (DA, 88%; DOPAC, 75%) than for WT mice (DA,
76%; DOPAC, 60%). The DA/DOPAC ratios were significantly
lower in METH-treated than in saline-treated mice, but did not
differ by genotype (Fig. 4C). METH significantly decreased stri-
atal 5-HT, but less severely than DA, and the effect was similar in
both genotypes ( p  0.05; 31% in WT and 38% in GDNF/)
(Fig. 4D).
At 12 months of age, there was a treatment (F(1,28)  20.1; p 
0.001) and genotypic (F(1,28)  15.7; p  0.001) effect, but no
interaction, for striatal levels of DA in saline-treated GDNF/
versus WT mice (Fig. 5A). There also was a treatment (F(1,28) 
10.8; p  0.01) and genotypic (F(1,28)  11.8; p  0.01) effect, but
no interaction, for the striatal levels of DOPAC (Fig. 5B), and a
significant treatment (F(1,28)  6.9; p  0.05) but no genotypic
effect on the DA/DOPAC ratio (Fig. 5C). Furthermore, there was
a treatment (F(1,28)  12.1; p  0.01) and genotypic (F(1,28) 
15.6; p  0.001) effect, but no interaction, for striatal levels of
5-HT (Fig. 5D). Additional analysis using a one-way ANOVA
(F(3,28)  9.2; p  0.001) and pairwise comparisons revealed that
5-HT was significantly less in GDNF/ than in WT mice that
were saline-treated ( p  0.05) (Fig. 5A–D). Importantly, 12-
month-old, METH-treated GDNF/ mice had significantly
lower levels of DA (46%), DOPAC (29%), and 5-HT (35%), but
similar DA/DOPAC ratios compared with METH-treated WT
mice (Fig. 5A–D), suggesting that lasting striatal damage to the
DA system after the adolescent METH binge is greater for the
combined effect of a GDNF deficiency and METH than for either
insult alone.
Striatal and plasma METH concentrations do not differ
between GDNF / and WT mice
In the course of exploring mechanistic bases for the exacerbation
of METH-induced neurotoxicity in GDNF/ versus WT mice,
the concentration of METH in the striatum and blood plasma
was determined 30, 60, 120, and 180 min after the last of four
METH injections in a separate set of mice. Figure 6A illustrates a
representative GC–MS–negative ion chemical ionization (NiCl)-
selected ion-monitoring chromatogram of METH (top ion pro-
file; tR  4.32 min) and the deuterated METH internal standard
(bottom ion profile, tR  4.28 min) extracted from a striatal
microsample. NiCl yielded selected ion chromatograms free of
chemical interferences. Fortified striatal tissue calibrators dem-
onstrated highly linear responses. This method was applied to
striatal tissue and blood plasma collected 30, 60, 120, and 180 min
after the last of four METH injections. No significant difference
in METH concentrations was found between genotypes at any of
the time points, either in striatal tissue or in blood plasma (Fig.
6B,C). Thus, enhanced METH toxicity cannot be attributed to
differences in METH concentrations in the brains of GDNF/
mice.
Figure 4. METH treatment resulted in a significant reduction in striatal tissue levels of DA
and 5-HT that did not differ between genotypes at 3 months of age (*p  0.05). A, B, D, Saline
(SAL)-treated GDNF / mice had higher tissue levels of DA (A) and DOPAC (B) than WT mice
( p  0.05), but there was no difference in 5-HT (D) tissue levels. METH treatment caused a
significant reduction in DA, DOPAC, and 5-HT tissue levels in WT and GDNF / mice ( p 
0.05). C, The DA/DOPAC ratio was not different between the genotypes treated with saline, and
the ratio was reduced similarly in both genotypes by METH treatment ( p  0.05). D, 5-HT
tissue levels were similar in saline-treated GDNF / and WT mice and were decreased to the
same extent by METH (*p  0.05; ***p  0.001). n  5 per group. Error bars indicate SEM.
Figure 5. METH-induced reductions in striatal DA, DOPAC, and 5-HT tissue levels are still
present at 12 months of age. A–D, Saline (SAL)-treated GDNF / mice have less striatal tissue
levels of DA (A) and 5-HT (D) than WT mice, but the striatal levels of DOPAC (B) and the DA/
DOPAC ratio (C) do not differ by genotype. METH-treated WT mice have less tissue DA, DOPAC,
DA/DOPAC, and 5-HT than saline-treated WT mice ( p  0.05). Furthermore, DA, DOPAC, and
5-HT levels were significantly lower in METH-treated GDNF / mice versus WT mice (*p 
0.05; ***p  0.001). n  8 per group. Error bars indicate SEM.
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Greater DAT activity may underlie
enhanced METH toxicity in
GDNF / mice
A two-by-two ANOVA indicated an age-
by-genotype interaction (F(1,20)  23.2;
p  0.001) for DAT activity data. A one-
way ANOVA (F(3,20)  83.8; p  0.001)
followed by Student–Neuman–Keuls
comparisons indicated that DAT activity
was significantly higher in striatal synapto-
somes from untreated GDNF/ versus
WT mice at both ages and that DAT activ-
ity was greater in GDNF/ mice at 12
months than at 3 months of age ( p  0.05)
(Fig. 7A). In contrast, DAT-IR in the
whole striatum did not differ according to
genotype at either age (Fig. 7B,C). Al-
though GDNF/ mice were not available
for DAT activity measurements after
METH treatment in this study, future
studies will determine DAT activity in
both genotypes after a METH binge.
Discussion
GDNF/ mice were more susceptible to
METH toxicity and age-related decline in
brain function than WT mice. Further-
more, long-term consequences of METH
toxicity, which emerged as the mice aged,
were more severe in GDNF/ mice.
Twelve-month-old GDNF/ mice
treated with saline when young had a
greater deficit in motor activity, lower stri-
atal TH-IR, DA, DOPAC, and 5-HT tissue
levels, higher DAT activity, and fewer TH-
positive SN DA neurons than age-matched
WT mice. In addition, a toxic METH binge
in young adult mice caused a greater reduction in TH-IR in the
lateral striatum, DA, and 5-HT markers and motor activity in
GDNF/ mice than in WT mice at 12 months of age. These data
substantiate previous reports that GDNF is an important regula-
tor of DA and motor-system function during aging (Hebert and
Gerhardt, 1998; Boger et al., 2006). Furthermore, this study
clearly establishes that damage to the nervous system as a conse-
quence of METH may be prolonged and that the absence of im-
mediate behavioral changes does not preclude the possibility that
deficits will be manifested at a later time in life. These data are
consistent with reports that significant loss of DAT activity in the
striatum of humans endures and accompanies psychomotor im-
pairments for many months after the end of METH use (Volkow
et al., 2001).
Although precise biological mechanisms were not identified,
the present study suggests that greater DAT activity, but not dif-
ferential METH accumulation in the brain, may underlie the
increased vulnerability of GDNF/ mice to METH. The greater
DAT activity of GDNF/ mice may have increased METH up-
take by striatal DAergic terminals resulting in more severe and/or
prolonged damage. The combination of less dense TH-IR inner-
vation in medial striatum coupled with greater striatal DA and
DOPAC tissue concentrations in GDNF/ mice suggests that
greater DAT activity is an adaptive mechanism that may keep
release and uptake in balance under resting conditions when the
mice are young. However, striatal levels of DA and DOPAC in
GDNF/ mice were less than in WT mice at 12 months of age,
despite persistent elevation in DAT activity, suggesting an imbal-
ance in DA function that emerges as GDNF/ mice age.
Greater loss of TH-IR in the lateral versus the medial striatum
of wild-type mice after METH treatment confirms previous re-
ports (Joyce et al., 2004; O’Callaghan and Miller, 1994; Koike et
al., 2005) and extends this observation to the striatum of mice 9.5
months after METH treatment. The reason for less TH-IR loss in
the medial versus lateral striatum of WT mice is unknown, but
may be attributable to a greater density of DAT normally in the
lateral striatum of rodents (Ciliax et al., 1995; Watanabe et al.,
2004; Zhu et al., 2005). In contrast, TH-IR loss in the medial
striatum was greater in GDNF/ mice than in WT mice, con-
sistent with an overall increase in striatal DAT activity in the
GDNF/ mice. In 12-month-old mice, however, the more se-
verely affected lateral striatum showed less recovery in both ge-
notypes. Functionally, the lateral striatum, which receives input
from the sensorimotor cortex and lateral substantia nigra, is
more highly correlated with most aspects of motor function
(Gerfen, 1984; McGeorge and Faull, 1989; Voorn et al., 2004) and
dysfunction in Parkinson’s disease (PD) (Brooks, 2003) than is
the medial striatum.
Three-month-old, saline-treated GDNF/ mice had greater
microglial activation than WT mice, but GDNF/ mice did not
demonstrate a loss of SN DAergic neurons until 12 months of age
when microgliosis was not detected in the SN. Microglial activa-
Figure 6. A, Representative GC–MS–NiCl-selected ion-monitoring chromatogram of METH (top; retention time, 4.32 min) and
internal standard deuterated METH (bottom; 4.28 min) extracted from a striatal microsample. B, C, Striatal METH concentration
(micrograms per milligram of tissue) (B) and plasma METH concentration (microgram per milliliter) (C) did not differ between WT
and GDNF / mice at 30, 60, 120, or 180 min after the fourth METH injection. n  5 per group per time point. Error bars indicate
SEM.
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tion has been associated with DAergic neurodegeneration ob-
served in PD patients and in animal models of the disease (Fran-
cis et al., 1995; Czlonkowska et al., 1996; Langston et al., 1999). In
addition, reactive microgliosis has been demonstrated in the stri-
atum, but not in the SN, within 1– 6 d after a toxic METH binge
(LaVoie et al., 2004; Thomas et al., 2004a,b). In this study, how-
ever, 2 weeks after mice underwent a METH binge, there was no
evidence of activated microglia in the striatum, but activated mi-
croglia were present in the SN, with the greatest activation seen in
METH-treated GDNF/ mice. It is likely that the increase in
CD45-IR in the SN 2 weeks after injection represented a slow
retrograde signal from striatal terminals to the cell body region of
DA neurons. These data indicate that subnormal GDNF levels
may allow a low level of inflammation that becomes exacerbated
when CNS injury occurs in vulnerable brain regions.
It is important to note that, despite an 80 – 86% reduction in
striatal tissue DA levels and a 52–58% decrease in 5-HT levels 2
weeks after the METH injections, spontaneous activity in an open
field was not altered in these mice. However, a motor deficit was
revealed when METH-treated mice were challenged with the DA
uptake blocker, nomifensine, suggesting that the DA system was
sufficiently intact to maintain basic motor function, but was un-
able to perform normally in response to a challenge. An alterna-
tive explanation for the absence of a motor deficit despite the
substantial striatal DA reduction in these young adult mice is that
nucleus accumbens DA was not influenced at 2 weeks post-
METH (supplemental Table 1, available at www.jneurosci.org as
supplemental material). Because the nucleus accumbens is also
involved in mediating locomotor activity (Mogenson and
Nielsen, 1983), this undisturbed pathway may also have contrib-
uted to the normal open field behavior in 3-month-old mice.
At 12 months of age, a reduction in motor activity emerged in
saline-treated GDNF/ mice that was positively correlated with
a reduction in striatal DA, DOPAC, and 5-HT levels, TH-IR in
lateral striatum, and a 26% cell loss in the SN not present at 3
months of age. Furthermore, a reduction in spontaneous motor
activity emerged in 9- and 12-month-old METH-treated mice
that was exacerbated in GDNF/ mice when they reached 12
months of age. Interestingly, decreases in striatal DA, DOPAC,
and 5-HT were also present in METH-treated mice that were
exacerbated in GDNF/ mice at this age, implying a connection.
Thus, slow recovery of TH, DA, and 5-HT systems from METH,
coupled with the age-related decline in DA and 5-HT systems in
GDNF/ mice, may underlie the exacerbated motor deficits in
GDNF/ mice at 12 months of age. Exacerbated reduction in
the function of the nigrostriatal DA system has consistently been
associated with greater decline in motor function with aging in
both humans (Suhara et al., 1991; Bannon et al., 1992; Volkow et
al., 1998) and animals (Emborg et al., 1998; Hebert and Gerhardt,
1998; Cass et al., 2005; Yurek and Fletcher-Turner, 2001).
Alterations in other neurotransmitter and signaling systems
may have contributed to the age-related motor deficits. Aging-
related decline in motor function has been associated with nor-
adrenergic (NE) deficits (Chan-Palay and Asan, 1989; Gesi et al.,
2000). Furthermore, 18-month-old GDNF/ mice have lower
NE concentrations and morphological alterations of NE cell bod-
ies in the locus ceruleus, lower NE transporter activity in the
cerebellum and brainstem, and fewer TH-positive fibers in the
hippocampus, cerebellum, and frontal cortex compared with
age-matched WT mice (Zaman et al., 2003). In addition, prelim-
inary microarray studies from our group indicate that both
-synuclein and the DA D2 receptor mRNA are upregulated in
the striatum of 12-month-old GDNF/ mice (Boger et al.,
2004), indicating multiple possible neurobiological substrates of
aging-related decline in these mice.
In summary, combining chronically lower GDNF levels with a
DA neurotoxin in young adult mice resulted in exacerbation of
DAergic system dysfunction during aging. Greater striatal DAT
activity in GDNF/ mice may underlie these genotypic differ-
ences in METH toxicity. Thus, lowered growth factor levels may
predispose individuals to greater acute and/or chronic conse-
quences of exposure to DA neurotoxins. Furthermore, METH
intoxication in any young adult may have deleterious behavioral
and neuronal consequences later in life, although a sustained
behavioral profile may not be apparent for many months (or
decades in humans) after the exposure. These studies speak di-
rectly to the possibility of protracted public health consequences
resulting from the current epidemic of METH abuse among
young adults.
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